BioDiscovery Releases NEXUS CGH for Analysis and Visualization of DNA Copy Number Data
BioDiscovery Inc., the leading developer of integrated software solutions for microarray-based research announced today the release of NEXUS CGH, a unique and novel tool for analysis of array CGH-based data from multi-array experiments supporting any platform, including Agilent, Nimblegen, Affymetrix, Illumina, Empire Genomics, and most home-spotted arrays.
El Segundo, CA (PRWEB) July 13, 2007 -- BioDiscovery Inc., the leading developer of integrated software solutions for microarray-based research, announced today the release of NEXUS CGH, a unique and novel tool for analysis of array CGH-based data from multi-array experiments supporting any platform, including Agilent, Nimblegen, Affymetrix, Illumina, Empire Genomics, and most home-spotted arrays.
NEXUS CGH is the only commercial software tool that can easily support large-scale array CGH-based experiments involving hundreds of samples from any platform, including high-density Agilent 244K arrays as well as Nimblegen 3 million probe tiling arrays. Its user-friendly interface allows the researcher to quickly identify potential regions of significant copy number changes in various biological categories (e.g., different grades of tumors) and extract a gene list for the smallest region of overlap in the sample set.
"Using NEXUS CGH, my lab has been able to quickly and confidently process large amounts of high-density array CGH data obtained from FFPE tumor samples to identify important chromosomal regions" said Dr. Jeff Gregg head of Molecular Pathology at UC Davis. "NEXUS CGH has allowed us to move from raw data into exploring CNV's and associated genes in a matter of few hours whereas this process might have taken months to complete with other commercial or academic packages."
"Our research laboratory is using a wide variety of array CGH platforms and analysis software. We have found NEXUS CGH to be very user-friendly and capable of handling a large number of datasets, simultaneously." says Dr. Charles Lee of Harvard Medical School.
"With NEXUS CGH we are addressing a growing market need for an easy-to-use yet powerful solution for performing copy number analysis" said Dr. Soheil Shams, BioDiscovery, CEO. "NEXUS CGH is a natural extension of our popular ImaGene CGH product designed to go from a single array analysis to encompass large scale multi-array studies. We are excited about the extremely positive initial user responses received from many of the major research labs using oligo as well as BAC arrays".
NEXUS CGH is currently only available through BioDiscovery's Early Adopter program and runs on OS X, Windows and Linux operating systems. Forged in close collaboration with leading cancer research centers, NEXUS CGH fills the gap between BioDiscovery's single array ImaGene CGH product and its Enterprise-wide integrated knowledge management system - ARM CGH.
About BioDiscovery
Founded in 1997 in Los Angeles, BioDiscovery is a leader in the development of microarray bioinformatics software and services. BioDiscovery develops and sells advanced software solutions and services that enable its customers to revolutionize drug discovery and diagnostics by efficiently managing, integrating, and analyzing data generated using high-throughput microarray technology. BioDiscovery provides a full line of modular software packages spanning the entire microarray process, including enterprise data management, image processing, data mining, statistical analysis, and collaborative knowledge management.
###
|
